INFEX Therapeutics
Andrew Wilkinson is an accomplished medicinal chemist with extensive experience in drug discovery and project leadership. Currently serving as a Research Leader in Medicinal Chemistry at INFEX Therapeutics since August 2017, Andrew successfully progressed a metallo-beta-lactamase inhibitor program from initial hits to preclinical candidate within two years. Prior to this, Andrew held various leadership roles at Redx Pharma and Almac Discovery, where significant contributions were made to the development of novel nuclear receptor modulators and oncology drug candidates. Andrew holds a PhD in Chemistry from Durham University, complemented by an MSci in Chemistry from the same institution.
This person is not in the org chart
This person is not in any teams
INFEX Therapeutics
We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.